keyword
MENU ▼
Read by QxMD icon Read
search

Protocol chemotherapy for lung cancer

keyword
https://www.readbyqxmd.com/read/28955007/phase-i-study-of-combined-therapy-with-vorinostat-and-gefitinib-to-treat-bim-deletion-polymorphism-associated-resistance-in-egfr-mutant-lung-cancer-victroy-j-a-study-protocol
#1
Shinji Takeuchi, Kenichi Yoshimura, Tadami Fujiwara, Masahiko Ando, Shinobu Shimizu, Katsuhiko Nagase, Yoshinori Hasegawa, Toshiaki Takahashi, Nobuyuki Katakami, Akira Inoue, Seiji Yano
The BIM deletion polymorphism is reported to be associated with poor outcomes of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) treated with EGFR-TKIs, including gefitinib. We have shown that a histone deacetylase inhibitor, vorinostat, can epigenetically restore BIM function and apoptosis sensitivity to EGFR-TKIs in EGFR-mutant NSCLC cells with BIM deletion polymorphisms. The purpose of this study is to determine the feasibility of combined treatment of vorinostat with gefitinib in BIM deletion polymorphism positive EGFR-mutant NSCLC patients...
2017: Journal of Medical Investigation: JMI
https://www.readbyqxmd.com/read/28955006/phase-i-ii-study-of-alectinib-in-lung-cancer-with-ret-fusion-gene-study-protocol
#2
Shinji Takeuchi, Toshinori Murayama, Kenichi Yoshimura, Takahiro Kawakami, Shizuko Takahara, Yasuhito Imai, Yoshikazu Kuribayashi, Katsuhiko Nagase, Koichi Goto, Makoto Nishio, Yoshinori Hasegawa, Miyako Satouchi, Katsuyuki Kiura, Takashi Seto, Seiji Yano
BACKGROUND: The rearranged during transfection (RET) fusion gene was discovered as a driver oncogene in 1-2% of non-small cell lung cancers (NSCLCs). Alectinib is an approved anaplastic lymphoma kinase (ALK) inhibitor that may also be effective for RET fusion-positive NSCLC. METHODS/DESIGN: RET fusion-positive NSCLC patients treated with at least one regimen of chemotherapy are being recruited. In step 1, alectinib (600 or 450 mg, twice daily) will be administered following a 3+3 design...
2017: Journal of Medical Investigation: JMI
https://www.readbyqxmd.com/read/28934231/principal-component-analysis-identifies-patterns-of-cytokine-expression-in-non-small-cell-lung-cancer-patients-undergoing-definitive-radiation-therapy
#3
Susannah G Ellsworth, Bryan M Rabatic, Jie Chen, Jing Zhao, Jeffrey Campbell, Weili Wang, Wenhu Pi, Paul Stanton, Martha Matuszak, Shruti Jolly, Amy Miller, Feng-Ming Kong
BACKGROUND/PURPOSE: Radiation treatment (RT) stimulates the release of many immunohumoral factors, complicating the identification of clinically significant cytokine expression patterns. This study used principal component analysis (PCA) to analyze cytokines in non-small cell lung cancer (NSCLC) patients undergoing RT and explore differences in changes after hypofractionated stereotactic body radiation therapy (SBRT) and conventionally fractionated RT (CFRT) without or with chemotherapy...
2017: PloS One
https://www.readbyqxmd.com/read/28915900/a-randomized-phase-ii-study-to-assess-the-effect-of-adjuvant-immunotherapy-using-%C3%AE-galcer-pulsed-dendritic-cells-in-the-patients-with-completely-resected-stage-ii-iiia-non-small-cell-lung-cancer-study-protocol-for-a-randomized-controlled-trial
#4
Hideo Saka, Chiyoe Kitagawa, Yukito Ichinose, Mitsuhiro Takenoyama, Hidenori Ibata, Tatsuo Kato, Koji Takami, Motohiro Yamashita, Tadashi Maeda, Sadanori Takeo, Hitoshi Ueda, Kan Okabayashi, Seiji Nagashima, Tadayuki Oka, Hidenori Kouso, Seiichi Fukuyama, Kentaro Yoshimoto, Mototsugu Shimokawa, Akiko M Saito, Suminobu Ito
BACKGROUND: As the toxicity associated with the α-GalCer-pulsed dendritic cell (DC) therapy could be considered to be negligible, its addition to postoperative adjuvant chemotherapy would be expected to greatly improve the therapeutic effect, and could result in prolonged survival. The aim of the present study is to compare the therapeutic efficacy of alpha-galactosylceramide-pulsed DC therapy in patients who have undergone a complete resection of stage II-IIIA non-small-cell lung cancer (NSCLC) followed by postoperative adjuvant therapy with cisplatin plus vinorelbine, to that in patients who did not receive additional treatment (surgical resection plus postoperative adjuvant chemotherapy only)...
September 15, 2017: Trials
https://www.readbyqxmd.com/read/28878202/predicting-organ-specific-risk-interactions-between-radiation-and-chemotherapy-in-secondary-cancer-survivors
#5
Venkata S K Manem, Clemens Grassberger, Harald Paganetti
Several studies have shown that pediatric patients have an increased risk of developing a secondary malignancy several decades after treatment with radiotherapy and chemotherapy. In this work, we use a biologically motivated mathematical formalism to estimate the relative risks of breast, lung and thyroid cancers in childhood cancer survivors due to concurrent therapy regimen. This model specifically includes possible organ-specific interaction between radiotherapy and chemotherapy. The model predicts relative risks for developing secondary cancers after chemotherapy in breast, lung and thyroid tissues, and compared with the epidemiological data...
September 6, 2017: Cancers
https://www.readbyqxmd.com/read/28875225/methodological-quality-evaluation-of-systematic-reviews-or-meta-analyses-on-ercc1-in-non-small-cell-lung-cancer-a-systematic-review
#6
REVIEW
Huan Tao, Yueyuan Zhang, Qian Li, Jin Chen
PURPOSES: To assess the methodological quality of systematic reviews (SRs) or meta-analysis concerning the predictive value of ERCC1 in platinum chemotherapy of non-small cell lung cancer. METHODS: We searched the PubMed, EMbase, Cochrane library, international prospective register of systematic reviews, Chinese BioMedical Literature Database, China National Knowledge Infrastructure, Wan Fang and VIP database for SRs or meta-analysis. The methodological quality of included literatures was evaluated by risk of bias in systematic review (ROBIS) scale...
November 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28866371/no-longer-any-role-for-routine-follow-up-chest-x-rays-in-men-with-stage-i-germ-cell-cancer
#7
MULTICENTER STUDY
H De La Pena, A Sharma, C Glicksman, J Joseph, M Subesinghe, Z Traill, C Verrill, M Sullivan, J Redgwell, E Bataillard, E Pintus, N Dallas, A Gogbashian, M Tuthill, A Protheroe, M Hall
Following radical orchidectomy for testicular cancer, most patients undergo protocolled surveillance to detect tumour recurrences rather than receive adjuvant chemotherapy. Current United Kingdom national and most international guidelines recommend that patients require a chest x-ray (CXR) and serum tumour markers at each follow-up visit as well as regular CT scans; there is however, variation among cancer centres with follow-up protocols. Seminomas often do not cause tumour marker elevation; therefore, CT scans are the main diagnostic tool for detecting relapse...
October 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28865463/carbon-ion-radiotherapy-for-non-small-cell-lung-cancer-with-interstitial-lung-disease-a%C3%A2-retrospective-analysis
#8
Mio Nakajima, Naoyoshi Yamamoto, Kazuhiko Hayashi, Masataka Karube, Daniel K Ebner, Wataru Takahashi, Makoto Anzai, Kenji Tsushima, Yuji Tada, Koichiro Tatsumi, Tadaaiki Miyamoto, Hiroshi Tsuji, Takehiko Fujisawa, Tadashi Kamada
BACKGROUND: Lung cancer is frequently complicated by interstitial lung disease (ILD). Treatment protocols for lung cancer patients with ILD have not been established; surgery, chemotherapy, and radiotherapy can all cause acute exacerbation of ILD. This study evaluated the toxicity and efficacy of carbon ion radiotherapy (CIRT) in patients with non-small cell lung cancer (NSCLC) and ILD. METHODS: Between June 2004 and November 2014, 29 patients diagnosed with NSCLC and ILD were treated with CIRT...
September 2, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28864605/radioembolization-of-colorectal-liver-metastases-indications-technique-and-outcomes
#9
REVIEW
F Edward Boas, Lisa Bodei, Constantinos T Sofocleous
Liver metastases are a major cause of death from colorectal cancer. Intraarterial therapy options for colorectal liver metastases include chemoinfusion via a hepatic arterial pump or port, irinotecan-loaded drug-eluting beads, and radioembolization using (90)Y microspheres. Intraarterial therapy allows the delivery of a high dose of chemotherapy or radiation into liver tumors while minimizing the impact on liver parenchyma and avoiding systemic effects. Specificity in intraarterial therapy can be achieved both through preferential arterial flow to the tumor and through selective catheter positioning...
September 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28838395/randomized-phase-ii-study-of-carboplatin-plus-irinotecan-versus-carboplatin-plus-amrubicin-in-patients-with-chemo-na%C3%A3-ve-extensive-stage-small-cell-lung-cancer-north-japan-lung-cancer-study-group-njlcg-0901
#10
Naoto Morikawa, Akira Inoue, Shunichi Sugawara, Makoto Maemondo, Toshiyuki Harada, Masao Harada, Yuka Fujita, Terufumi Katoh, Hiroshi Yokouchi, Hiroshi Watanabe, Kazuhiro Usui, Toshiro Suzuki, Jun Sakakibara-Konishi, Hiroki Nagai, Mariko Kanbe, Toshihiro Nukiwa
OBJECTIVE: Carboplatin-based regimens are the standard regimens for patients with extensive-stage small-cell lung cancer (ES-SCLC). However, the efficacies of these regimens are unsatisfactory. We previously identified carboplatin plus irinotecan (CI) and carboplatin plus amrubicin (CA) as promising new carboplatin-based regimens. Accordingly, we conducted a randomized phase II study to identify the appropriate regimen for future phase III trials. MATERIALS AND METHODS: Chemotherapy-naïve patients with ES-SCLC were randomly assigned to receive 4-6 cycles of carboplatin [area under the curve (AUC) 5...
September 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28757800/case-report-recurrent-mucoepidermoid-carcinoma-of-the-tongue-in-adult-female-patient-with-lung-cancer
#11
Arielle Rubin, John Davis, Karim Jreije, Henry Wu, Randy Oppenheimer
There is a steady rise in incidence of malignant salivary gland tumors in the United States, with mucoepidermoid carcinoma (MEC) the most frequent. Although 40% of MECs are found in the parotid gland, these lesions possess the capacity to develop anywhere along the aerodigestive tract. Here, we present a case of recurrent tongue MEC in a young adult female patient with history of lung malignancy and multiple brain metastases. Without a universally accepted management protocol for recurrent MECs, the current clinical practice uses tumor grade, location, and clinical progression to determine both prognosis and goals of care...
2017: Clinical Medicine Insights. Ear, Nose and Throat
https://www.readbyqxmd.com/read/28686055/a-stakeholder-informed-randomized-controlled-comparative-effectiveness-study-of-an-order-prescribing-intervention-to-improve-colony-stimulating-factor-use-for-cancer-patients-receiving-myelosuppressive-chemotherapy-the-tracer-study
#12
Aasthaa Bansal, Sean D Sullivan, Dawn L Hershman, Gary H Lyman, William E Barlow, Jeannine S McCune, Scott D Ramsey
Colony stimulating factors (CSF) are widely prescribed to avoid febrile neutropenia (FN) among cancer patients receiving chemotherapy, but studies show their use is often not consistent with practice guidelines. In addition, there is limited high quality evidence assessing benefits and harms of primary prophylactic-CSF (PP-CSF) in the setting of chemotherapy that poses an intermediate risk of FN. To address these issues, with funding from the Patient Centered Outcomes Research Institute (PCORI) and the National Cancer Institute's Community Oncology Research Program, SWOG is sponsoring a prospective, cluster randomized controlled pragmatic trial of an automated order entry protocol for PP-CSF among patients with breast, lung and colorectal cancer receiving myelosuppressive chemotherapy, with a nested randomized controlled trial of PP-CSF for patients receiving intermediate risk chemotherapy...
July 7, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28668204/randomized-phase-iii-study-of-cisplatin-with-pemetrexed-and-cisplatin-with-vinorelbine-for-completely-resected-nonsquamous-non-small-cell-lung-cancer-the-jipang-study-protocol
#13
Nobuyuki Yamamoto, Hirotsugu Kenmotsu, Takeharu Yamanaka, Shinichiro Nakamura, Masahiro Tsuboi
This trial report describes the background and design for the Japan Intergroup Trial of Pemetrexed Adjuvant Chemotherapy for Completely Resected Nonsquamous Non-Small-Cell Lung Cancer (JIPANG) study (University Hospital Medical Information Network database: UMIN000006737). Various randomized trials have shown the efficacy of postoperative adjuvant chemotherapy regimens that include cisplatin for resected non-small-cell lung cancer (NSCLC), but the optimal regimen is not known. The JIPANG study is a randomized study comparing cisplatin (75 mg/m(2), day 1) and pemetrexed (500 mg/m(2), day 1) with cisplatin (80 mg/m(2), day 1) and vinorelbine (25 mg/m(2), days 1 and 8) for nonsquamous NSCLC as postoperative adjuvant chemotherapy...
June 8, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28549414/phase-i-ii-study-of-induction-chemotherapy-using-carboplatin-plus-irinotecan-and-sequential-thoracic-radiotherapy-trt-for-elderly-patients-with-limited-disease-small-cell-lung-cancer-ld-sclc-torg-0604
#14
Yuki Misumi, Hiroaki Okamoto, Jiichiro Sasaki, Noriyuki Masuda, Mari Ishii, Tsuneo Shimokawa, Yukio Hosomi, Yusuke Okuma, Makoto Nagamata, Takashi Ogura, Terufumi Kato, Masafumi Sata, Sakiko Otani, Akira Takakura, Koichi Minato, Yosuke Miura, Takuma Yokoyama, Saori Takata, Katsuhiko Naoki, Koshiro Watanabe
BACKGROUND: The role of irinotecan for elderly patients with LD-SCLC has been unclear, and the timing of TRT combined with chemotherapy has not been fully evaluated. METHODS: Patients aged > 70 years with untreated, measurable, LD-SCLC, performance status (PS) 0-2, and adequate organ function were eligible. Treatment consisted of induction with carboplatin on day 1 and irinotecan on days 1 and 8, every 21 days for 4 cycles, and sequential TRT (54Gy in 27 fractions)...
May 26, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28530214/-the-long-term-treatment-outcomes-of-adult-osteosarcoma
#15
Iwowa Ługowska, Andrzej Pieńkowski, Anna Szumera-Ciećkiewicz, Hanna Koseła-Paterczyk, Pawel Teterycz, Maciej Głogowski, Katarzyna Kozak, Anna Klimczak, Slawomir Falkowski, Piotr Rutkowski
Osteosarcoma is the most common primary bone tumor. Treatment of osteosarcoma patients is based on chemotherapy as well as surgical resection of primary tumor and distant metastases. Lung metastases are the primary cause of death in this group of patients. AIM: The aim of this study is to summarize the 20 years of osteosarcoma treatment outcomes in the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology in Warsaw. MATERIALS AND METHODS: Our analysis included clinical data of 299 osteosarcoma patients aged between 14 and 81 years (median 32) treated in Maria Sklodowska-Curie Memorial Cancer Center between 1998 and 2016...
April 21, 2017: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/28453801/does-perioperative-chemotherapy-improve-survival-in-patients-with-resectable-lung-metastases-of-colorectal-cancer
#16
REVIEW
Francesco Guerrera, Pierre-Emmanuel Falcoz, Stephane Renaud, Gilbert Massard
A best evidence topic was constructed according to a structured protocol. The question addressed was whether the administration of perioperative chemotherapy (CT) is effective in improving survival in patients with resectable lung metastases of colorectal cancer (CRC). Of the 44 papers found using a report search, 6 investigated the effect of perioperative CT (adjuvant-CT, preoperative-CT or both) on outcomes in patients undergoing lung metastasectomy for CRC. These 6 studies presented the best evidence to answer the clinical question...
May 1, 2017: Interactive Cardiovascular and Thoracic Surgery
https://www.readbyqxmd.com/read/28437852/a-diagnostic-microdosing-approach-to-investigate-platinum-sensitivity-in-non-small-cell-lung-cancer
#17
Si-Si Wang, Maike Zimmermann, Hongyong Zhang, Tzu-Yin Lin, Michael Malfatti, Kurt Haack, Kenneth W Turteltaub, George D Cimino, Ralph de Vere White, Chong-Xian Pan, Paul T Henderson
The platinum-based drugs cisplatin, carboplatin and oxaliplatin are often used for chemotherapy, but drug resistance is common. The prediction of resistance to these drugs via genomics is a challenging problem since hundreds of genes are involved. A possible alternative is to use mass spectrometry to determine the propensity for cells to form drug-DNA adducts-the pharmacodynamic drug-target complex for this class of drugs. The feasibility of predictive diagnostic microdosing was assessed in non-small cell lung cancer (NSCLC) cell culture and a pilot clinical trial...
August 1, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28362511/effect-of-accurate-heart-delineation-on-cardiac-dose-during-the-convert-trial
#18
RANDOMIZED CONTROLLED TRIAL
Nicki Groom, Elena Wilson, Corinne Faivre-Finn
OBJECTIVE: This study investigated the effect of deviation from protocol in heart delineation for the Concurrent Once-daily Versus twice-daily Radiotherapy (CONVERT) Trial ( ClinicalTrials.gov Identifier NCT00433563) quality assurance (QA) programme and the effect of that on mean cardiac dose and percentage of heart volume receiving ≥5 Gy (V5%) and percentage of heart volume receiving ≥30 Gy (V30%). METHODS: Patients with limited-stage small-cell lung cancer in the CONVERT trial were randomized to receive 45 Gy in 30# twice daily or 66 Gy in 33# once daily radiotherapy, with concurrent chemotherapy in both arms...
May 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28344046/long-term-outcomes-of-induction-carboplatin-and-gemcitabine-followed-by-concurrent-radiotherapy-with-low-dose-paclitaxel-and-gemcitabine-for-stage-iii-non-small-cell-lung%C3%A2-cancer
#19
Catherine Guilbault, Aurelie Garant, Sergio Faria, Scott Owen, Linda Ofiara, Marie Duclos, Vera Hirsh, Neil Kopek
BACKGROUND: Standard treatment for unresectable stage III non-small-cell lung cancer (NSCLC) is concurrent chemo-radiation (CRT). A regimen of induction carboplatin and gemcitabine followed by CRT was developed at the McGill University Health Centre to prevent delays in treatment initiation. We report the long-term outcomes with this regimen based on a pooled analysis of both protocol patients from a phase II study and nonprotocol patients. METHODS AND MATERIALS: Outcomes and toxicity data were retrieved for 142 patients with stage III NSCLC: 43 patients treated on protocol between January 2003 and November 2004, and 101 patients treated off-protocol between December 2004 and August 2013...
March 1, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28287519/endobronchial-ultrasound-guided-intratumoral-injection-of-cisplatin-for-the-treatment-of-isolated-mediastinal-recurrence-of-lung-cancer
#20
Hiren J Mehta, Michael A Jantz
Isolated hilar and mediastinal recurrence (IMHR) following external beam radiation therapy (EBRT) in patients with lung cancer is common. These patients do not have many treatment options and are usually offered palliative chemotherapy or best supportive care. Endobronchial ultrasound (EBUS)-guided intratumoral injection of cisplatin (ITC) is a novel approach for these patients. The procedure is performed under conscious sedation. The lesion is located with a bronchoscopy using EBUS, and a 22-gauge EBUS needle is advanced through the working channel of the scope and locked in position...
February 12, 2017: Journal of Visualized Experiments: JoVE
keyword
keyword
109129
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"